◈ Nootpedia
Compact view
Research pass: quick Peptide · Intranasal NOT-RELEVANT LOW

GB-115

Extended Research
◈ Extended Research ◈

Our depth — beyond the mirror

Deeper analysis, verdict reasoning, and per-archetype recommendations from our research team.

▸ Our verdict NOT-RELEVANT LOW

Sparse Russian-only data + unreliable gray-market sourcing + Selank already covers Dylan's anxiolytic role with a multi-mechanism profile and a 17-year clinical track record. GB-115 is mechanistically interesting (CCK-B antagonism is the panic-disorder axis) but offers Dylan no incremental benefit over what Selank delivers. Verdict would upgrade to WATCH-LIST if (a) Western RCT data emerged, (b) Dylan develops panic-disorder-flavored anxiety that Selank's GABA/enkephalinase axis fails to address, or (c) sourcing stabilizes with verified COA.

Research pass: quick
▸ Decision matrix by user profile Per-archetype
  • Dylan20-30, brain-priority, high cognitive workload (Dylan-archetype)
    NOT-RELEVANT

    Selank covers the anxiolytic role with better evidence, multi-mechanism breadth, and reliable sourcing. GB-115 adds nothing Dylan needs.

  • 30-50, executive maintenance
    NOT-RELEVANT

    for the same reasons.

  • 50+, mild cognitive decline
    NOT-RELEVANT

    No cognitive benefit; not the target use case.

  • Anxiety-prone (generalized)
    OPTIONAL-ADD

    at most. Selank or buspirone are higher-evidence options.

  • Panic-disorder phenotype (CCK-mediated panic, sudden-onset somatic panic)
    WATCH-LIST

    This is the one population where GB-115's mechanism actually shines theoretically — selective CCK-B antagonism is the panic-disorder pharmacology. But the evidence base is still too thin to recommend over established options (SSRIs, propranolol, Selank).

  • High athletic load, tested status
    NOT-RELEVANT

    Not a meaningful tool for athletic anxiety; WADA status uncharacterized.

  • Sleep-disordered
    NOT-RELEVANT
  • Recovery-focused
    NOT-RELEVANT
  • Strength/anabolic-focused
    NOT-RELEVANT
▸ Subjective experience (deep)

Onset: 15-30 minutes sublingual per Russian sources.

Peak: ~1-2 hours, duration ~4-6 hours.

Characteristic effects (per sparse anecdotal reports):

  • Mild anxiolytic effect — "took the edge off"
  • No sedation
  • No cognitive lift (unlike Selank's mild cognitive-bright signature)
  • No mood-bright (unlike Selank's enkephalinase-driven warmth)
  • Often described as "didn't really feel anything" by users with low baseline anxiety

Variability: High. Some users report meaningful pre-event anxiolysis; many report sub-threshold effect. Likely depends on whether the user's anxiety has a CCK-mediated panic flavor vs more diffuse anxiety phenotypes. Users with panic-disorder symptoms (sudden-onset, somatic, high-arousal panic episodes) may be the responders; users with generalized anxiety / cognitive worry may not see effect.

▸ Tolerance + cycling deep dive
  • Tolerance buildup: Unknown. CCK-B receptor antagonism does not have a well-characterized tolerance pathway, but no formal study has examined this.
  • Recommended cycle: Russian convention defaults to 14-21 day courses with 7-14 day breaks for most investigational peptide compounds. Apply this conservatively if used.
  • Reset protocol: Not characterized.
▸ Stacking deep dive

Synergistic with

  • Theoretically complementary with selank (different mechanism: CCK-B antagonism vs GABA-A PAM + enkephalinase). But the practical use case for stacking is thin — Selank already provides robust anxiolysis for Dylan's profile, and adding GB-115 introduces sourcing risk + opportunity cost without clear marginal benefit. Skip the stack; Selank dominates this slot.

Avoid stacking with

  • Nothing specifically contraindicated based on mechanism. CCK-B antagonism doesn't overlap with GABAergics, serotonergics, or opioids.

Neutral / safe co-administration

  • Mechanism does not predict adverse interactions with Dylan's V4 base or V5 daily-tier compounds. But absence of data ≠ absence of risk.
▸ Drug interactions deep dive
  • No documented CYP induction/inhibition in available literature (peptide-class compound; metabolism likely peptidase-mediated).
  • GABAergics: No mechanism overlap. Theoretically additive anxiolysis; no respiratory depression risk.
  • Serotonergics: No documented interactions.
  • Practical bottom line: Drug interaction profile largely uncharacterized; treat as unknown for any concurrent prescription medication.
▸ Pharmacogenomics

No data. CCK / CCKBR polymorphisms exist (rs1799923 in CCKBR has been studied for panic-disorder susceptibility) but no clinical data on whether they predict GB-115 response.

▸ Sourcing deep dive
Path Vendor Cost Reliability Notes
Gray-market Russian RUPharma ~$30-50 / box (intermittent) Low-Medium Stock highly intermittent; often listed as "out of stock" for months at a time.
Gray-market Russian CosmicNootropic ~$30-50 / box (intermittent) Low-Medium Same intermittent-stock issue as RUPharma.
Research-chem Various US/EU peptide vendors Variable Low No COA verification standard for this compound; molecular ID confirmation difficult outside specialized labs.

Sourcing reality: GB-115 is one of the harder-to-source Russian investigational compounds. Even the established Russian vendors (RUPharma, CosmicNootropic) carry it inconsistently. Western research-chem vendors occasionally list it but COA practices for an obscure dipeptide are unreliable. Practical conclusion: even if Dylan wanted it, getting a verified, in-stock supply chain is genuinely difficult.

▸ Biomarkers to track (deep)

If used (low priority for Dylan):

  • Baseline: subjective anxiety VAS, panic-attack frequency log
  • During use: weekly anxiety VAS, panic-episode log, basic LFT/CBC at 4 and 12 weeks (precaution given sparse safety data)
  • Post-cycle: subjective anxiety vs baseline 2 weeks post-cessation
▸ Controversies / open debates Live debate

  1. Russian-only evidence + investigational status. GB-115 never crossed into Western pharmaceutical development despite the CCK-B antagonist mechanism being a real and parallel Western pharmacology target (devazepide, L-365,260, CI-988). Western development largely abandoned CCK-B antagonists for clinical anxiety after mixed Phase II results in the 1990s — meaning the broader pharmacology class has been investigated and partially failed in Western settings, casting some shadow on GB-115's specific clinical promise.

  2. Mechanism vs effect-size mismatch. CCK-B antagonism is theoretically a clean anxiolytic axis, but Western trials of similar compounds in panic-disorder didn't show breakthrough efficacy. Whether GB-115 is meaningfully different (different chemistry, different binding profile) or whether it shares the same effect-size limitation as other CCK-B antagonists is unclear from available data.

  3. GB-115 vs Selank for Dylan's specific use case. Selank wins decisively on (a) evidence base depth, (b) mechanism breadth (5+ pathways vs 1), (c) sourcing reliability, (d) clinical track record (17+ years Russian Rx use). The only scenario where GB-115 might pull ahead is panic-disorder-flavored anxiety in a user where Selank's GABA/enkephalinase axis is insufficient — and Dylan does not have this profile.

▸ Verdict change log
  • 2026-05-06 — Initial verdict: NOT-RELEVANT for Dylan / verdict-confidence LOW. Selank dominates the anxiolytic slot with better evidence, broader mechanism, reliable sourcing, and 17-year clinical track record. GB-115 offers no incremental benefit for Dylan's use case (pre-sparring / pre-call performance anxiety, generalized cognitive workload). Verdict would upgrade to WATCH-LIST only if (a) Dylan develops panic-disorder phenotype Selank can't address, (b) Western RCT data emerges, or (c) a verified-COA, reliably-stocked supply chain materializes.
▸ Open questions / gaps Open
  1. No Western RCT data. Replication of Russian panic-disorder / GAD findings in a Western clinical setting would be the single highest-leverage data point.
  2. Plasma PK and bioavailability not well-characterized in English literature.
  3. Long-term safety (>3 month continuous) unstudied in healthy gray-market users.
  4. Tolerance pathway uncharacterized — does CCK-B receptor downregulate with chronic antagonism?
  5. Pharmacogenomic predictors of response (CCKBR rs1799923 etc.) — entirely unstudied.
  6. Head-to-head vs Selank, vs SSRIs, vs propranolol — does not exist.
▸ Sources (full, with our context)
Back to compact view